Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGAV | P06756 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12374514 | 0.88 | AAK1 (0.41) | P4HBHIF1AAAK1CA1CA2 | |
| SCHEMBL3273502 | 0.88 | P4HB (0.44) | P4HBHIF1AAAK1CA1CA2 | |
| SCHEMBL3273490 | 0.88 | P4HB (0.44) | P4HBHIF1AAAK1CA1CA2 | |
| SCHEMBL12374513 | 0.84 | NPR3 (0.39) | P4HBHIF1AAAK1CYP19A1 | |
| SCHEMBL14204179 | 0.84 | NPR3 (0.39) | P4HBHIF1AAAK1CYP19A1 | |
| SCHEMBL12374511 | 0.84 | P4HB (0.44) | P4HBHIF1A | |
| SCHEMBL2282459 | 0.82 | AAK1 (0.38) | P4HBHIF1AAAK1CA1CA2 | |
| SCHEMBL2282455 | 0.82 | AAK1 (0.38) | P4HBHIF1AAAK1CA1CA2 | |
| SCHEMBL2282462 | 0.82 | AAK1 (0.38) | P4HBHIF1AAAK1CA1CA2 | |
| SCHEMBL2286260 | 0.82 | P4HB (0.36) | P4HBHIF1AAAK1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2008053182-A1 | IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | IRAK3, IKBKE, IRAK1 | P4HB 2786/4885HIF1A 2523/4885AAK1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.